INTRODUCTION
============

Pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), hold great promise in many biomedical fields. Indefinite proliferation of PSCs provides an unlimited cell source. Pluripotent differentiation potential enables PSCs to generate any desired cell type *in vitro*. PSC-derived cells such as neurons are particularly valuable for human due to the lack of alternative sources. Therefore, generation of functional and fully differentiated cells from PSCs has been an active field of stem cell research. Common strategies rely on a vast knowledge of developmental biology learned from animal studies. Small molecules and recombinant signaling proteins have been applied to PSC differentiation in order to derive specific lineage cells. Despite the attempt to faithfully mimic *in vivo* development, these approaches suffer from several major limitations. The first limitation is that procedures are time-consuming. Neural differentiation, for example, usually takes 4\~6 weeks and functional maturation requires a few more months depending on neuronal subtypes ([@b52-molce-42-3-200]; [@b63-molce-42-3-200]). The second limitation is variability with low purity. Dramatic difference in differentiation potentials across particular PSC lines has been well documented in recent studies ([@b6-molce-42-3-200]; [@b20-molce-42-3-200]; [@b25-molce-42-3-200]; [@b26-molce-42-3-200]; [@b27-molce-42-3-200]; [@b40-molce-42-3-200]; [@b62-molce-42-3-200]). This variability influences the response of PSCs to signaling molecules, resulting in different purity of desired cell types. Furthermore, difficulty in quality control of small molecules and recombinant proteins adds more variability to protocols. Given that large scale production of mature cells with high purity is necessary for clinical applications, alternative strategies might shed light on how to produce disease-relevant cell types from PSCs.

During embryonic development, cell fates are determined by a network of transcription factors. Consistently, successful reprogramming of cell fates by forced induction of single or a combination of transcription factors has been reported. Most strikingly, overexpression of four transcription factors (OCT4, SOX2, KLF4, c-MYC) can reprogram fibroblasts to PSCs ([@b47-molce-42-3-200]). In some cases, single transcription factor is sufficient for direct reprogramming of fibroblasts to other cell types such as neurons and myoblasts ([@b9-molce-42-3-200]; [@b14-molce-42-3-200]). These examples are very striking because cell fate acquisition relies on sequential requirement of multiple transcription factors over the course of development according to traditional views. To test the feasibility of transcription factor-directed PSC differentiation, systemic induction of transcription factors has been performed in mouse ESCs (mESCs)([@b10-molce-42-3-200]; [@b39-molce-42-3-200]). Interestingly, 63 out of 137 transcription factors were able to initiate and direct specific differentiation programs when they were induced individually, suggesting that transcription factor induction could be an efficient strategy to direct PSC differentiation. In this review, we present PSC differentiation methods based on transcription factor induction. Potential limitations of this approach and possible solutions are also discussed.

NEURONS
=======

Producing functionally mature neurons from human PSCs (hPSCs) is important to understand normal physiology of human neurons and pathology of neurological diseases. Conventional methods follow the developmental path of neuronal derivation. First, PSCs are differentiated into neural progenitor cells (NPCs) by embryoid body formation or dual SMAD inhibition ([@b8-molce-42-3-200]). After that, NPCs are directed into specific neurons by a combination of signaling molecules ([@b46-molce-42-3-200]; [@b52-molce-42-3-200]). Based on the finding that forced expression of three transcription factors (BRN2, ASCL1, and MYT1L) can reprogram mouse fibroblasts into functional neurons ([@b57-molce-42-3-200]), whether the same combination of transcription factors could bypass the long developmental path from hPSCs to neurons has been tested ([@b42-molce-42-3-200]). Surprisingly, hPSCs expressing these three transcription factors showed bipolar neuron-like morphologies as early as day 3. They expressed neuronal markers such as β-III-tubulin (also known as Tuj1) and MAP2 by day 8. Electrophysiological analysis showed that these hPSC-derived neurons generated action potentials as early as day 6. The rapid induction of neuronal fate implicates that transcription factor induction can bypass sequential developmental stages and drive direct differentiation of hPSCs into neurons. More strikingly, a single transcription factor, ASCL1, was sufficient to drive direct neuronal differentiation of both human and mouse PSCs ([@b9-molce-42-3-200]; [@b42-molce-42-3-200]; [@b65-molce-42-3-200]). BRN2 and MYT1L likely contribute to neuronal maturation by increasing morphological complexity. ASCL1 induction during mESC differentiation increased the percentage of neural cells (PSA-NCAM+) from less than 5% (no ASCL1 induction) to almost 50%, highlighting the robustness of transcription factor-directed differentiation ([@b65-molce-42-3-200]). Other transcription factors previously known to play important roles in neurogenesis were also tested. Ectopic expression of NEUROG2 can efficiently drive mouse and human PSCs into pure excitatory neurons in less than two weeks ([@b54-molce-42-3-200]; [@b67-molce-42-3-200]). These NEUROG2-directed neurons showed neuronal transcription profiles, formed synapses, and produced robust action potentials. Furthermore, when these human neurons were transplanted into mouse brain, functional integration and active electrophysiological properties were observed ([@b67-molce-42-3-200]), suggesting potential applications of these neurons for cell replacement therapy. Forced induction of another proneural transcription factor, NEUROD1, also drove rapid differentiation of hPSCs into excitatory neurons ([@b67-molce-42-3-200]).

GABAergic interneurons are inhibitory neurons that balance neuronal excitation in the brain. Given that the majority of cortical interneurons are originated from the medial ganglionic eminence (MGE)([@b61-molce-42-3-200]), four transcription factors (ASCL1, DLX2, NKX2.1, and LHX6) have been chosen based on their expression in the MGE ([@b45-molce-42-3-200]). Through extensive comparison, a combination of three transcription factors (ASCL1, DLX2, and LHX6) has been found to be able to drive hPSCs into GABA and MAP2 double-positive neurons within 10 days ([@b45-molce-42-3-200]). Co-expression of miR-9/9\* and miR-124 further increased the efficiency of interneuron derivation. These GABAergic interneurons exhibited electrophysiological properties within 6\~8 weeks and functionally integrated into the host's neural circuit upon transplantation to mouse brain ([@b45-molce-42-3-200]). In another study, co-expression of ASCL1 and DLX2 was sufficient to differentiate hPSCs into GA-BAergic interneurons with \~90% efficiency ([@b66-molce-42-3-200]). These interneurons showed electrophysiological properties at five weeks after transcription factor induction and survived well in the transplanted mouse brain. Interestingly, ASCL1 also contributed to the conversion of hPSCs into dopaminergic neurons when it was co-expressed with NURR1 and LMX1A ([@b53-molce-42-3-200]). This combination of transcription factors produced mature and functional dopaminergic neurons within 21 days.

Motor neurons are typically produced from PSC-derived NPCs that are caudalized and ventralized by retinoic acid and sonic hedgehog, respectively ([@b32-molce-42-3-200]; [@b60-molce-42-3-200]). These methods suffer from a long and inefficient differentiation process. To overcome such problem, motor neuron-specifying transcription factors have been identified based on temporal gene expression analysis upon retinoic acid/sonic hedgehog treatment ([@b19-molce-42-3-200]). Forced expression of three transcription factors, NEUROG2, ISL1, and LHX3, in hPSC-derived NPCs accelerated motor neuron differentiation ([@b19-molce-42-3-200]). At day 11 post transcription factor induction, cells expressed motor neuron markers HB9 and CHAT, formed neuromuscular junctions, and exhibited electrophysiological properties. Given that conventional methods using retinoic acid and sonic hedgehog take \~45 days to acquire mature motor neurons, transcription factor-directed motor neuron derivation could be a faster and more efficient alternative method. ISL1--LHX3 fusion proteins can also drive mESCs into mature motor neurons in the absence of sonic hedgehog by suppressing a spinal interneuron fate ([@b31-molce-42-3-200]).

Many studies described above used a lentiviral vector for transcription factor delivery because this viral vector could infect PSCs in a highly efficient manner and drive stable expression of transgenes by host genome integration. However, host genome modifications could be a potential problem in terms of using transcription factor-directed differentiation methods in a clinical setting. To circumvent this issue, researchers have exploited alternative gene deliver tools such as protein transduction, synthetic mRNAs, and non-integrating viral vectors. For example, a cocktail of synthetic mRNAs encoding five transcription factors (NEUROG1, NEUROG2, NEUROG3, NEUROD1, and NEUROD2) induced rapid differentiation of hPSCs toward neurons ([@b17-molce-42-3-200]). Synthetic mRNA-directed neurons showed electrophysiological properties as early as 7 days after mRNA transfection. A combination of synthetic mRNAs encoding ATOH1 and NEUROG2 was also tested to differentiate hiP-SCs into mature dopaminergic neurons ([@b64-molce-42-3-200]). Delivery of three transcription factors, LHX3, NEUROG2, and ISL1, by non-integrating Sendai virus vectors efficiently drove hPSCs into HB9-positive and ChAT-positive motor neurons within two weeks after transduction ([@b18-molce-42-3-200]). These examples suggest that transcription factor-directed differentiation methods can be further improved for clinical applications. The methods described above are summarized in [Table 1](#t1-molce-42-3-200){ref-type="table"}.

PANCREATIC β-CELLS
==================

β-cells are a type of endocrine cells in the pancreas that can produce insulins to control blood glucose levels. Because transplantation of β-cells is a promising approach to treat diabetes patients, many researchers have been working on generating functional β-cells from PSCs. Common and conventional methods for β-cell derivation follow the developmental process of pancreas ([@b56-molce-42-3-200]). PSCs are first induced into definitive endoderm which is further specified into pancreatic lineage cells. To facilitate β-cell differentiation, PAX4, an essential transcription factor for β-cell development, is overexpressed in mESCs ([@b5-molce-42-3-200]). Constitutive expression of PAX4 increased the formation of insulin-producing cells from 10\~20% to 60\~80%. Furthermore, transplantation of PAX4-directed insulin-producing cells maintained normal blood glucose levels in streptozotocin-induced diabetic mice.

Other studies have also confirmed that forced induction of PAX4 could be an efficient method to derive insulin-producing β-cells from mouse and human PSCs ([@b33-molce-42-3-200]; [@b34-molce-42-3-200]). Other transcription factors that play key roles in pancreatic development have also been tested in PSCs. Forced expression of PDX1 could facilitate mESC differentiation toward insulin-producing cells although these cells lacked mature properties such as high insulin secretion and glucose-responsiveness ([@b38-molce-42-3-200]). It has been reported that biphasic induction of PDX1 that mimic the normal development of pancreatic β-cells had better effects on mouse and human ESC differentiation than constitutive expression ([@b4-molce-42-3-200]). The ESC-derived β-cells secreted insulins and C-peptides. However, they failed to respond to glucose stimulation, suggesting that PDX1 alone might not be sufficient for mature β-cell derivation from PSCs. However, a later study reported that mESC-derived insulin-producing cells by PDX1 overexpression were glucose-responsive. They reduced hyperglycemia when they were transplanted into streptozotocin-induced diabetic mice ([@b43-molce-42-3-200]). Such discrepancy could be due to different differentiation media conditions used to differentiate PDX1-expressing ESCs into insulin-producing cells. PDX1 induction has also been proven to be useful for β-cell derivation when it is combined with other transcription factors such as NKX6.1 and NEUROG3 ([@b21-molce-42-3-200]; [@b29-molce-42-3-200]; [@b58-molce-42-3-200]). Moreover, it has been reported that induction of NKX2.2 alone can result in appearance of insulin-producing cells (stained by Dithizone) as early as 14 days in mESC-derived embryoid bodies although glucose-dependent secretion is not observed ([@b44-molce-42-3-200]). Overall, forced induction of pancreatic transcription factors tested so far can drive a pancreatic β-cell fate from PSCs, although functional maturation might require other transcription factor networks.

Transcription factor-directed methods for pancreatic β-cell differentiation are summarized in [Table 2](#t2-molce-42-3-200){ref-type="table"}.

SKELETAL AND CARDIAC MUSCLES
============================

Muscular dystrophies including Duchenne muscular dystrophy and limb girdle muscular dystrophy are inherited disorders with skeletal muscle degeneration ([@b36-molce-42-3-200]). PSC-derived skeletal muscles could be a promising source for transplantation therapy and disease modeling. Based on previous findings that MYOD1, a master transcription factor of myogenesis, can convert non-muscle cells into skeletal myocytes ([@b14-molce-42-3-200]; [@b59-molce-42-3-200]), whether MYOD1 induction could direct PSCs into skeletal muscles has been tested. MYOD1 overexpression facilitated myogenesis in mESC-derived embryoid bodies and generated skeletal muscle fibers ([@b15-molce-42-3-200]). However, only a subset of differentiating cells could be differentiated into skeletal muscles. Other studies have also confirmed that MYOD1 overexpression can induce myogenesis in mESCs ([@b41-molce-42-3-200]; [@b65-molce-42-3-200]). Interestingly, MYOD1 is unable to induce the myogenic program in hESCs, although extensive myogenic conversion has been observed in human fibroblasts ([@b2-molce-42-3-200]). However, co-expression of SWI/SNF component BAF60C (encoded by SMARCD3) and MYOD1 is capable of driving hESCs into muscle cells, suggesting that the presence of epigenetic barriers can block MYOD1 functions in hESCs ([@b2-molce-42-3-200]). BAF60C2/MYOD1-directed myospheres showed spontaneous contraction as well as typical skeletal muscle markers (myogenin, MyH3, and MyH8) at 20 days after differentiation. Ectopic expression of the catalytic domain of histone demethylase JMJD3 also enabled MYOD1 to activate the myogenic program in hPSCs ([@b1-molce-42-3-200]). However, another study has been reported that MYOD1 alone is sufficient to drive hiPSCs into skeletal muscles ([@b51-molce-42-3-200]). Such difference could be attributed to different media conditions used for muscle differentiation or variability related to hESC and hiPSC lines. More studies are warranted in order to make a clear answer to this issue.

PAX3 is a key transcription factor that initiates myogenesis in early paraxial mesoderm. Consistently, forced expression of PAX3 in mESC-derived embryoid bodies can greatly promote myogenic differentiation ([@b11-molce-42-3-200]). Myo-genic progenitor cells can be further enriched from PAX3-directed cells by sorting out a PDGFαR^+^Flk1^−^ population. Transplantation of PAX3-directed PDGFαR^+^Flk1^−^ cells has shown potential for therapeutic engraftment in dystrophic mice ([@b11-molce-42-3-200]). Like PAX3, overexpression of PAX7 can also efficiently drive both human and mouse ESCs into muscle progenitor cells with muscle regeneration potential ([@b12-molce-42-3-200], [@b13-molce-42-3-200]).

To facilitate myocardial differentiation, transient overexpression of ISL1, a cardiac progenitor marker, has been tested in mESCs. Transfection of mESC-derived embryoid bodies with a ISL1-expressing construct increased the expression of cardiomyocyte markers (ACTC1, MLC2V, MYH7, SMA), suggesting an instructive role of ISL1 in myocardial differentiation ([@b30-molce-42-3-200]). The effect of ISL1 on myocardial differentiation has also been confirmed in hESCs by ISL1 protein transduction ([@b16-molce-42-3-200]). A combined delivery of three transcription factors, GATA4, MEF2C, and TBX5, to mESC-derived embryoid bodies activated the cardiac program and increased the efficiency of cardiomyocyte derivation up to 60% ([@b3-molce-42-3-200]). Another combination of five transcription factors, GATA4, MEF2C, TBX5, ESRRG and MESP1, has been tested in hPSCs. Delivery of these transcription factors to hPSC-derived mesoderm strongly promoted cardiomyocyte differentiation ([@b24-molce-42-3-200]). Furthermore, a single transcription factor, SHOX2, greatly facilitated the derivation of cardiac pacemaker cells when it was delivered into mESC-derived embryoid bodies ([@b23-molce-42-3-200]). Most SHOX2-directed embryoid bodies exhibited spontaneous beating. When they were transplanted to the left ventricular apex of rat heart, SHOX2-directed embryoid bodies functioned as biopacemakers. Thus, many attempts with single or a combination of transcription factors have been made to produce functional muscle cells from PSCs. However, it seems that transcription factor-directed differentiation methods are not yet mature enough to produce highly pure muscle cells with functional maturity in a short culture period. New combinations of transcription factors together with small-molecule epigenetic inhibitors should be tested to further improve PSC-derived muscle derivation in the future. Transcription factor-directed methods for muscle cell differentiation are summarized in [Table 3](#t3-molce-42-3-200){ref-type="table"}.

HEPATOCYTES
===========

Liver transplantation is a promising treatment for end-stage liver diseases. PSC-derived hepatocytes could not only be unlimited sources for cell therapy, but also serve as an experimental model for metabolic diseases. Several key transcription factors for liver development have been tested to develop directed PSC differentiation methods. HEX (also known as HHEX) is an essential transcription factor that functions at the early stage of hepatic development. Forced expression of HEX in mESC-derived endoderm can dramatically increase the expression of genes related to hepatocyte maturation and function ([@b28-molce-42-3-200]). These findings have also been confirmed in hPSCs ([@b22-molce-42-3-200]). hPSCs were differentiated into definitive endoderm by Activin A followed by adenoviral delivery of HEX. Transient overexpression of HEX was sufficient to promote hepatocyte derivation. HEX-directed cells expressed both α-fetoprotein (AFP) and albumin (ALB) on day 12. Furthermore, P450 cytochrome enzymes known to play a critical role in liver metabolism were also expressed in HEX-directed hepatoblasts ([@b22-molce-42-3-200]). Further maturation of hepatoblasts into functional hepatocytes was achieved by overexpression of HNF4α, a key regulator of liver-specific genes ([@b49-molce-42-3-200]). Interestingly, forced induction of HNF4α in mESCs was able to bypass the natural order of hepatic differentiation and activate the hepatic program directly from mESCs ([@b65-molce-42-3-200]). ALB secretion and the uptake of low-density lipoproteins were observed in HNF4α-directed cells as early as 7 days after differentiation. In their study, other transcription factors, such as FOXA1, GATA2, and GATA3, could also directly drive mESCs into hepatocytes ([@b65-molce-42-3-200]).

Sequential delivery of transcription factors has also been tested for efficient PSC differentiation toward hepatocytes ([@b48-molce-42-3-200]; [@b50-molce-42-3-200]). Forced induction of either SOX17 or FOXA2 was used to differentiate hPSCs into definitive endoderm. SOX17-directed endoderm cells were driven to hepatocytes by HEX overexpression ([@b48-molce-42-3-200]). In FOXA2-directed endoderm cells, HNF1α transduction efficiently generated hepatocytes ([@b50-molce-42-3-200]). Furthermore, a single-step protocol with a combination of transcription factors for hepatocyte derivation has been reported ([@b55-molce-42-3-200]). Forced induction of four transcription factors, CEBPA, CEBPB, FOXA1, and FOXA3, directly differentiated hiPSCs into hepatocytes when they were cultured in a medium that could promote hepatic differentiation. Transcription factor-directed methods for hepatocyte differentiation are summarized in [Table 4](#t4-molce-42-3-200){ref-type="table"}.

CONCLUSIONS
===========

During development, fully differentiated cells emerge through several intermediate stages. For example, ESCs first produce early neuroectoderm that gives rise to region-specific neural progenitor cells. Neural progenitor cells further differentiate into post-mitotic neurons, a type of fully differentiated cells in the brain. Even in this simplified description, the end-stage cell fate is derived through three sequential cell fate transitions. An outstanding question in developmental biology is if multiple transitions are necessary for the acquisition of fully differentiated cell fates. A growing body of recent evidence shows that cell fate acquisition/conversion can occur directly by forced expression of transcription factors, suggesting that multiple developmental steps are unnecessary for generating fully differentiated cells. In this review, we also described examples of direct conversion of PSCs into mature cell types by transcription factors. Overexpression of transcription factors related to late developmental stages could bypass early developmental processes and rapidly produce functionally mature cells from PSCs. This is especially prominent in neuronal differentiation because many studies have shown that single proneural transcription factor is sufficient to convert PSCs into functional neurons with almost 100% efficiency. However, transcription factor-directed PSC differentiation seems to be less effective in other lineages. Although transcription factor induction can promote lineage differentiation, protocols are not yet mature in terms of efficiency or functional maturity. In some cases, transcription factors failed to initiate the differentiation program in PSCs likely due to epigenetic barriers. Small-molecule epigenetic inhibitors could be helpful to reset PSCs to be responsive to late-stage transcription factors.

Despite major advantages of transcription factor-directed differentiation over conventional methods, current methods are not ready for clinical applications yet. Besides a few tests for functionality, extensive systemic analyses including transcriptome and epigenome should be performed to validate if transcription factor-directed cells are safe and mature as their *in vivo* counterparts. Furthermore, virus-mediated transcription factor delivery might be inappropriate for clinical settings. Alternative delivery methods such as protein transduction and synthetic RNA transfection are under active investigation. Given that simple and scalable differentiation procedures with high purity are major bottlenecks for therapeutic applications of PSC-derived cells, transcription factor-directed PSC differentiation methods could be used as a promising strategy for future cell therapy.
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###### 

Transcription factor-directed PSC differentiation toward neurons

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cell Line     Final Cell Type       Transcription Factor                                                                  Delivery Method         Time to Functional Cell   Differentiation Efficiency           Functional Test                                                        Therapeutic Effect   Reference
  ------------- --------------------- ------------------------------------------------------------------------------------- ----------------------- ------------------------- ------------------------------------ ---------------------------------------------------------------------- -------------------- -----------------------
  mESC          Excitatory neuron     NEUROG2                                                                               Stable transfection     \~10 days                 40% (TuJ1^+^)                        Electrophysiology\                                                     ND                   [@b54-molce-42-3-200]
                                                                                                                                                                                                                   Coculture with primary neurons                                                              

  mESC          Excitatory neuron     ASCL1                                                                                 Lentiviral vector       \~5 days                  ND                                   Electrophysiology                                                      ND                   [@b9-molce-42-3-200]

  hESC          \~28 days                                                                                                                                                                                                                                                                                      

  hESC, hiPSC   Excitatory neuron     Either NEUROG2 or NEUROD1                                                             Lentiviral vector       \~2 weeks                 \~100% (MAP2^+^), \~100% (NeuN^+^)   Electrophysiology\                                                     ND                   [@b67-molce-42-3-200]
                                                                                                                                                                                                                   Calcium imaging\                                                                            
                                                                                                                                                                                                                   Transplantation into mouse brain                                                            

  hESC          Excitatory neuron     NEUROG2, SATB2, FEZF2                                                                 Lentiviral vector       \~35 days                 NEUROG2: 83% (MAP2^+^)\              Electrophysiology\                                                     ND                   [@b37-molce-42-3-200]
                                                                                                                                                                              NEUROG2+FEZF2: 64% (MAP2^+^)\        Transplantion into organotypic slice cultures of adult human cortex.                        
                                                                                                                                                                              NEUROG2+SATB2: 49% (MAP2^+^)                                                                                                     

  hESC          GABAergic neuron      ASCL1[a](#tfn1-molce-42-3-200){ref-type="table-fn"}, DLX2, LHX6, miR-9/9\*, miR-124   Lentiviral vector       \~6 weeks                 81.3% (MAP2^+^)\                     Electrophysiology\                                                     ND                   [@b45-molce-42-3-200]
                                                                                                                                                                              84.5% (GABA^+^/MAP2^+^)              Transplantation into mouse brain                                                            

  hESC          GABAergic neuron      ASCL1, DLX2                                                                           Lentiviral vector       \~5 weeks                 89.1% (GABA^+^/MAP2^+^)              Electrophysiology\                                                     ND                   [@b66-molce-42-3-200]
                                                                                                                                                                                                                   Transplantation into mouse brain                                                            

  hiPSC         Dopaminergic neuron   ASCL1, NURR1, LMX1A                                                                   Lentiviral vector       \~21 days                 51% (TuJ1^+^)                        Electrophysiology\                                                     ND                   [@b53-molce-42-3-200]
                                                                                                                                                                                                                   Dapamine release\                                                                           
                                                                                                                                                                                                                   Transplantation into mouse brain                                                            

  hiPSC         Dopaminergic neuron   ATOH1, NEUROG2                                                                        Synthetic mRNA          36--49 days               \>90% (TuJ1^+^)\                     Electrophysiology\                                                     ND                   [@b64-molce-42-3-200]
                                                                                                                                                                              \>97% (TH^+^/TuJ1^+^)                Dopamine release                                                                            

  hESC, hiPSC   Motor neuron          NEUROG2, ISL1, LHX3                                                                   Adenoviral vector       \~21 days                 49\~72% (HB9^+^CHAT^+^)              Electrophysiology\                                                     ND                   [@b19-molce-42-3-200]
                                                                                                                                                                                                                   Coculture with C2C12-derived myotubes                                                       

  hESC, hiPSC   Motor neuron          NEUROG1, NEUROG2, NEUROG3, NEUROD1, NEUROD2                                           Synthetic mRNA          \~7 days                  98.2% (TuJ1^+^)\                     Electrophysiology\                                                     ND                   [@b17-molce-42-3-200]
                                                                                                                                                                              83.2% (MAP2^+^/TuJ1^+^)\             Calcium imaging                                                                             
                                                                                                                                                                              94.3% (HB9^+^/TuJ1^+^)\                                                                                                          
                                                                                                                                                                              97.7% (ChAT^+^/TuJ1^+^)\                                                                                                         
                                                                                                                                                                              100% (ISL1^+^/TuJ1^+^)                                                                                                           

  hiPSC         Motor neuron          LHX3, NEUROG2, ISL1                                                                   Sendai virus vector     \~14 days                 \>90% (TuJ1^+^), \>90% (HB9^+^)      Electrophysiology\                                                     ND                   [@b18-molce-42-3-200]
                                                                                                                                                                                                                   Coculture with human myocytes                                                               

  mESC          Motor neuron          ISL1--LHX3 fusion protein                                                             Genetic recombination   \~6 days                  77% (HB9^+^/TuJ1^+^)                 Coculture with C2C12-derived myotubes                                  ND                   [@b31-molce-42-3-200]

  hESC, hiPSC   Neuron                BRN2, ASCL1, MYT1L                                                                    Lentiviral vector       \~6 days                  ND                                   Electrophysiology                                                      ND                   [@b42-molce-42-3-200]

  hESC          Neuron                Either NEUROG1, NEUROG2, NEUROG3, NEUROD1, or NEUROD2.                                PiggyBac vector         \~7 days                  40\~90% (HuC/D^+^)                   Electrophysiology\                                                     ND                   [@b35-molce-42-3-200]
                                                                                                                                                                                                                   Calcium imaging                                                                             

  hiPSC         Neuron                NEUROG1, NEUROG2                                                                      Lentiviral vector       \~14 days                 \>90% (MAP2^+^), \>90% (SYN1^+^)     Electrophysiology                                                      ND                   [@b7-molce-42-3-200]

  mESC          Neuron                Ascl1                                                                                 Genetic recombination   \~11 days                 8.3% (TH^+^/TuJ1^+^)\                Electrophysiology                                                      ND                   [@b65-molce-42-3-200]
                                                                                                                                                                              37.6% (ISL1^+^/TuJ1^+^)\                                                                                                         
                                                                                                                                                                              27.2% (GABA^+^/TuJ1^+^)                                                                                                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ASCL1: mutant form of ASCL1 in which five serine residues are substituted with alanine

ND: Not Determined

###### 

Transcription factor-directed PSC differentiation toward pancreatic β-cells

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cell Line   Final Cell Type             Transcription Factor                                              Delivery Method         Time to Functional Cell   Differentiation Efficiency   Functional Test                                                     Therapeutic Effect                             Reference
  ----------- --------------------------- ----------------------------------------------------------------- ----------------------- ------------------------- ---------------------------- ------------------------------------------------------------------- ---------------------------------------------- -----------------------
  mESC        Insulin-producing cell      PAX4                                                              Stable transfection     \~36 days                 80% (Insulin^+^)             Insulin release\                                                    Reduce blood glucose levels in diabetic mice   [@b5-molce-42-3-200]
                                                                                                                                                                                           Transplantation to diabetic mice                                                                                   

  mESC        Insulin-producing cell      PAX4                                                              Plasmid transfection    \~18 days                 55% (Insulin^+^)             Insulin release\                                                    Reduce blood glucose levels in diabetic mice   [@b34-molce-42-3-200]
                                                                                                                                                                                           Transplantation to diabetic mice                                                                                   

  hESC        Pancreatic β-cell           PAX4                                                              Stable transfection     \~28 days                 ND                           Proinsulin synthesis\                                               ND                                             [@b33-molce-42-3-200]
                                                                                                                                                                                           C-peptide release                                                                                                  

  hESC        Pancreatic β-cell           PDX1-VP16[a](#tfn3-molce-42-3-200){ref-type="table-fn"}           Stable transfection     \~17 days                 ND                           Insulin expression                                                  ND                                             [@b4-molce-42-3-200]

  mESC        \~28 days                   32% (C-peptide^+^)                                                Insulin release\                                                                                                                                                                                  
                                                                                                            C-peptide release                                                                                                                                                                                 

  mESC        Insulin-producing cell      PDX1                                                              Genetic recombination   16--24 days               ND                           Insulin release\                                                    No effect                                      [@b38-molce-42-3-200]
                                                                                                                                                                                           C-peptide expression                                                                                               

  mESC        Insulin-producing cell      PDX1-AcGFP fusion protein                                         Stable transfection     \~23 days                 25\~30% (Insulin^+^)         Insulin release\                                                    Reduce blood glucose levels in diabetic mice   [@b43-molce-42-3-200]
                                                                                                                                                                                           Transplantation to diabetic mice                                                                                   

  hiPSC       Insulin-producing cell      PDX1-VP16[a](#tfn3-molce-42-3-200){ref-type="table-fn"}, NKX6.1   Lentiviral vector       \~17 days                 ND                           Insulin release\                                                    ND                                             [@b58-molce-42-3-200]
                                                                                                                                                                                           C-peptide expression                                                                                               

  hESC        Pancreatic endocrine cell   PDX1, NKX6.1, siPOU5F1                                            Synthetic mRNA          \~13 days                 5.6% (Insulin^+^)            Insulin, glucagon, and somatostatin expression                      ND                                             [@b21-molce-42-3-200]

  mESC        Insulin-producing cell      PDX1, NEUROG3                                                     Genetic recombination   \~18 days                 43% (Insulin^+^)             Insulin expression\                                                 ND                                             [@b29-molce-42-3-200]
                                                                                                                                                                                           C-peptide, glucagon, and somatostatin release                                                                      

  mESC        Insulin-producing cell      NKX2.2                                                            Stable transfection     \~14 days                 1% (Dithizone^+^)            Dithizone[b](#tfn4-molce-42-3-200){ref-type="table-fn"} staining\   ND                                             [@b44-molce-42-3-200]
                                                                                                                                                                                           Insulin release                                                                                                    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PDX1 fused to the transactivator domain of the VP16 proteins from herpes simplex

A zinc-chelating agent known to stain β-cell

ND: Not Determined

###### 

Transcription factor-directed PSC differentiation toward skeletal and cardiac muscle cells

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cell Line     Final Cell Type                Transcription Factor               Delivery Method                                     Time to Functional Cell   Differentiation Efficiency    Functional Test                                      Therapeutic Effect                                                                                                   Reference
  ------------- ------------------------------ ---------------------------------- --------------------------------------------------- ------------------------- ----------------------------- ---------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- -----------------------
  mESC          Skeletal muscle                MYOD1                              Plasmid transfection                                \>13 days                 20--50%                       Skeletal muscle marker expression                    ND                                                                                                                   [@b15-molce-42-3-200]

  mESC          Myocyte                        MYOD1                              Genetic recombination                               \~5 days                  \~60% (MHC^+^Myogenin^+^)     Skeletal muscle marker expression\                   ND                                                                                                                   [@b65-molce-42-3-200]
                                                                                                                                                                                              Cell fusion assay with C2C12 mouse myoblast cells                                                                                                                         

  hiPSC         Skeletal myocyte               MYOD1                              PiggyBac vector                                     \~9 days                  70--90% (MHC^+^)              Skeletal muscle marker expression\                   ND                                                                                                                   [@b51-molce-42-3-200]
                                                                                                                                                                                              Cell fusion assay with C2C12 mouse myoblast cells\                                                                                                                        
                                                                                                                                                                                              Transplantation to mice                                                                                                                                                   

  mESC          Skeletal muscle                MyoD                               Genetic recombination                               \~6 days                  66% (MHC^+^)\                 Skeletal muscle marker expression\                   ND                                                                                                                   [@b41-molce-42-3-200]
                                                                                                                                                                23% (dystrophin^+^)           Transplantation to mice                                                                                                                                                   

  hESC          Skeletal muscle                BAF60C2, MYOD1                     Lentiviral vector                                   \~20 days                 60.1%(MHC^+^)                 Skeletal muscle marker expression\                   ND                                                                                                                   [@b2-molce-42-3-200]
                                                                                                                                                                                              Intracellular calcium recording\                                                                                                                                          
                                                                                                                                                                                              Contractile properties                                                                                                                                                    

  hESC          Skeletal muscle                JMJD3, MYOD1                       JMJD3: PiggyBac vector\                             \~5 days                  57% (MHC^+^)                  Skeletal muscle marker expression\                   ND                                                                                                                   [@b1-molce-42-3-200]
                                                                                  MYOD1: Synthetic mRNA                                                                                       Contractile properties                                                                                                                                                    

  hESC, hiPSC   Synthetic mRNA                 34\~64% (MHC^+^)                   Skeletal muscle marker expression\                                                                                                                                                                                                                                                    
                                                                                  Cell fusion assay with C2C12 mouse myoblast cells                                                                                                                                                                                                                                     

  mESC          Skeletal myogenic progenitor   PAX3                               Genetic recombination                               \~12 days                 72.2% (Myogenin^+^)\          Myogenic progenitor marker expression\               Improved isometric tetanic force and rotarod performance in mdx mice[a](#tfn6-molce-42-3-200){ref-type="table-fn"}   [@b11-molce-42-3-200]
                                                                                                                                                                78.4%(MHC^+^)                 Transplantation to mice\                                                                                                                                                  
                                                                                                                                                                                              Contractile properties                                                                                                                                                    

  mESC          Skeletal myogenic progenitor   PAX7                               Genetic recombination                               \~5 days                  84.4%(MHC^+^)                 Myogenic progenitor marker expression\               Improved isometric tetanic force in cardiotoxin-injured mdx mice                                                     [@b12-molce-42-3-200]
                                                                                                                                                                                              Transplantation to mice\                                                                                                                                                  
                                                                                                                                                                                              Contractile properties                                                                                                                                                    

  hESC, hiPSC   Skeletal myogenic progenitor   PAX7                               Lentiviral vector                                   \~14 days                 87\~91% (Myogenin^+^)\        Myogenic progenitor marker expression\               Improved isometric tetanic force in immunodeficient mdx mice                                                         [@b13-molce-42-3-200]
                                                                                                                                                                93\~96% (MHC^+^)              Transplantation to mice\                                                                                                                                                  
                                                                                                                                                                                              Contractile properties                                                                                                                                                    

  mESC          Cardiomyocyte                  ISL1                               Plasmid transfection                                \~8 days                  4.01%(Myh7^+^)                Cardiomyocyte marker expression                      ND                                                                                                                   [@b30-molce-42-3-200]

  hESC          Cardiomyocyte                  ISL1                               Protein transduction                                \~8 days                  75% (beating area)            Cardiomyocyte marker expression\                     ND                                                                                                                   [@b16-molce-42-3-200]
                                                                                                                                                                                              Spontaneous contractile properties                                                                                                                                        

  mESC          Cardiomyocyte                  GATA4, MEF2C, TBX5                 Bacterial injection                                 \~12 days                 61% (MHC^+^)                  Cardiomyocyte marker expression\                     ND                                                                                                                   [@b3-molce-42-3-200]
                                                                                                                                                                                              Spontaneous contractile properties                                                                                                                                        

  hESC, hiPSC   Cardiomyocyte                  GATA4, MEF2C, TBX5, ESRRG, MESP1   Bacterial injection                                 \~14 days                 55\~62%(cTnT^+^)              Cardiomyocyte marker expression\                     ND                                                                                                                   [@b24-molce-42-3-200]
                                                                                                                                                                                              Spontaneous contractile properties                                                                                                                                        

  mESC          Cardiac pacemaker cell         SHOX2                              Adenoviral vector                                   \~10 days                 83% (beating embryoid body)   Electrophysiological properties\                     Induced biological pacing in rat hearts                                                                              [@b23-molce-42-3-200]
                                                                                                                                                                                              Transplantation to the rat heart                                                                                                                                          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

mdx mice: mouse model for Duchenne muscular dystrophy (DMD)

ND: Not Determined

###### 

Transcription factor-directed PSC differentiation toward hepatocytes

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cell Line     Final Cell Type   Transcription Factor                   Delivery Method                 Time to Functional Cell   Differentiation Efficiency   Functional Test                             Therapeutic Effect   Reference
  ------------- ----------------- -------------------------------------- ------------------------------- ------------------------- ---------------------------- ------------------------------------------- -------------------- -----------------------
  mESC          Hepatocyte        HEX                                    Genetic recombination           \~14 days                 ND                           Hepatocyte marker expression\               ND                   [@b28-molce-42-3-200]
                                                                                                                                                                Liver metabolism-related gene expression                         

  hESC, hiPSC   Hepatocyte        HEX                                    Adenoviral vector               \~18 days                 \~84% (ALB^+^)\              Hepatocyte marker expression\               ND                   [@b22-molce-42-3-200]
                                                                                                                                   \~80% (CYP3A4^+^)\           Liver metabolism-related gene expression\                        
                                                                                                                                   \~88% (CYP7A1^+^)\           Liver metabolite production                                      
                                                                                                                                   \~92% (Cytokeratin18^+^)                                                                      

  hESC, hiPSC   Hepatocyte        SOX17, HEX, HNF4A                      Adenoviral vector               \~20 days                 \~80% (ALB^+^)\              Hepatocyte marker expression\               ND                   [@b49-molce-42-3-200]
                                                                                                                                   \~80% (CYP3A4^+^)\           LDL uptake\                                                      
                                                                                                                                   \~80% (CYP7A1^+^)\           Liver metabolism-related gene expression\                        
                                                                                                                                   \~80% (CYP2D6+)              Liver metabolite production\                                     
                                                                                                                                                                Glycogen storage\                                                
                                                                                                                                                                Indocyanine green (ICG) uptake                                   

  hESC, hiPSC   Hepatocyte        SOX17, HEX                             Adenoviral vector               \~18 days                 ND                           Hepatocyte marker expression\               ND                   [@b48-molce-42-3-200]
                                                                                                                                                                Liver metabolism-related gene expression                         

  hESC, hiPSC   Hepatocyte        FOXA2, HNF1A                           Adenoviral vector               \~20 days                 \~90% (ALB^+^)               Hepatocyte marker expression\               ND                   [@b50-molce-42-3-200]
                                                                                                                                                                LDL uptake\                                                      
                                                                                                                                                                Liver metabolism-related geneexpression\                         
                                                                                                                                                                Liver metabolite production\                                     
                                                                                                                                                                Glycogen storage\                                                
                                                                                                                                                                Indocyanine green (ICG) uptake\                                  
                                                                                                                                                                Urea secretion\                                                  
                                                                                                                                                                Drug metabolism capacity                                         

  hiPSC         Hepatocyte        CEBPA, CEBPB, FOXA1, FOXA3             Plasmid transfection            \~7 days                  ND                           Hepatocyte marker expression                ND                   [@b55-molce-42-3-200]

  mESC          Hepatocyte        Either HNF4A, FOXA1, GATA2, or GATA3   Genetic recombination           7--14 days                ND                           Hepatocyte marker expression\               ND                   [@b65-molce-42-3-200]
                                                                                                                                                                Albumin secretion\                                               
                                                                                                                                                                LDL uptake\                                                      
                                                                                                                                                                Glycogen storage                                                 

  HNF4A         Synthetic mRNA    \~11 days                              Hepatocyte marker expression\                                                                                                                           
                                                                         Glycogen storage                                                                                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ND: Not Determined
